Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP

Pacilio, Massimiliano; Ventroni, Guido; Basile, Chiara; Ialongo, Pasquale; Becci, D.; Mango, Lucio

doi:10.1007/s00259-013-2552-2

Cited by 31 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Then the activity at t=0 was estimated assuming full physical retention [27], and the percentage uptake was calculated by dividing the activity at t=0 by the administered activity (referred to below as B 99m Tc percent uptake^). The correlations between 99m Tc percent uptake of the lesion and the corresponding 223 Ra percent uptake, the corresponding cumulated activity and the absorbed dose from 223 Ra were determined by linear regression analysis.…”

Section: Correlation Between 99m Tc and 223 Ra Uptakementioning

confidence: 99%

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

Pacilio

Ventroni

Vincentis

et al. 2015

Eur J Nucl Med Mol Imaging

Self Cite

125

109

View full text Add to dashboard Cite

The feasibility of in vivo quantitative imaging in (223)Ra therapy was confirmed. The lesion uptake of (223)Ra-dichloride was significantly correlated with that of (99m)Tc-MDP. The D RBE to lesions per unit administered activity was much higher than that of other bone-seeking radiopharmaceuticals, but considering a standard administration of 21 MBq (six injections of 50 kBq/kg to a 70-kg patient), the mean cumulative value of D RBE was about 19 Gy, and was therefore in the range of those of other radiopharmaceuticals. The macrodosimetry of bone metastases in treatments with (223)Ra-dichloride is feasible, but more work is needed to demonstrate its helpfulness in predicting clinical outcomes.

show abstract

Section: Correlation Between 99m Tc and 223 Ra Uptakementioning

confidence: 99%

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride

Pacilio

Ventroni

Vincentis

et al. 2015

Eur J Nucl Med Mol Imaging

Self Cite

125

109

View full text Add to dashboard Cite

show abstract

“… 22 – 25 Correlations between the absorbed dose delivered to the red marrow and toxicity have been found for treatments with 153 Sm EDTMP. 26 …”

Section: Pharmacokinetics and Dosimetrymentioning

confidence: 99%

Imaging and dosimetry for radium-223: the potential for personalized treatment

Flux

2017

The British Journal of Radiology

View full text Add to dashboard Cite

Radium-223 (223Ra) offers a new option for the treatment of bone metastases from prostate cancer. As cancer treatment progresses towards personalization, the potential for an individualized approach is exemplified in treatments with radiotherapeutics due to the unique ability to image in vivo the uptake and retention of the therapeutic agent. This is unmatched in any other field of medicine. Currently, 223Ra is administered according to standard fixed administrations, modified according to patient weight. Although gamma emissions comprise only 1% of the total emitted energy, there are increasing reports that quantitative imaging is feasible and can facilitate patient-specific dosimetry. The aim of this article is to review the application of imaging and dosimetry for 223Ra and to consider the potential for treatment optimization accordingly, in order to ensure clinical and cost effectiveness of this promising agent.

show abstract

“…The eventual presence of a contemporary gamma emission by the nuclide utilized also allows the execution of scintigraphic investigations after its administration, useful for monitoring the distribution of the radio-pharmaceutical in the body and make the most of the time a predictive estimation of the dose received from the target compared to the administered activity [3].…”

Section: Editorialmentioning

confidence: 99%